You Searched For: Patient+Underpads

Catalog Number: (KIMB7093)

Supplier: KIMBERLY CLARK

Description: Single use, green protection sheets for use in busy healthcare environments.

UOM: 1 * 100 items

Sale

Supplier: KIMBERLY CLARK

Description: SCOTT® couch covers are strong, tear resistant and durable.

Supplier: KIMBERLY CLARK

Description: This two ply couch cover is strong, tear resistant and durable.

Catalog Number: (SCAA125250)

Supplier: Essity

Description: Hygienic couch cover rolls for protection of patient couches made from strong fibres.

UOM: 1 * 9 Roll

Sale

Supplier: Zellstoff-Vertriebs-GmbH & Co. KG

Description: The zetMedica® products are designed to prepare treatment facilities in a medical practice or hospital for the next patient between the individual examinations.

Supplier: VWR Collection

Description: Absorbent underpads with a three-layer construction made from PP top and back sheets and a cellulose filler.

Supplier: VWR Collection

Description: Sturdy container for transport of biological samples taken at patient’s home.

Catalog Number: (S4651-72EA)

Supplier: SIGMA-ALDRICH MICROSCOPY

Description: Silane-prep slides are microscope slides coated with silane (aminoalkysilane) to improve the adhesion of tissues to the slide for immunohistochemistry. The slide includes a 'frosted end' for slide/patient identification. It is not tested for use in microarray assays.

UOM: 1 * 72 items

Sale

Supplier: Biotium

Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, CMV is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of CMV disease. An indicator of active CMV infection is needed to facilitate the diagnosis of CMV disease in patients with AIDS or HIV infection. CMV p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.

Supplier: Biotium

Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, CMV is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of CMV disease. An indicator of active CMV infection is needed to facilitate the diagnosis of CMV disease in patients with AIDS or HIV infection. CMV p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.

Supplier: Biotium

Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, CMV is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of CMV disease. An indicator of active CMV infection is needed to facilitate the diagnosis of CMV disease in patients with AIDS or HIV infection. CMV p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.

Supplier: Biotium

Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, CMV is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of CMV disease. An indicator of active CMV infection is needed to facilitate the diagnosis of CMV disease in patients with AIDS or HIV infection. CMV p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.

Supplier: Biotium

Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, CMV is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of CMV disease. An indicator of active CMV infection is needed to facilitate the diagnosis of CMV disease in patients with AIDS or HIV infection. CMV p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.

Supplier: Biotium

Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, CMV is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of CMV disease. An indicator of active CMV infection is needed to facilitate the diagnosis of CMV disease in patients with AIDS or HIV infection. CMV p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.

Supplier: Biotium

Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, CMV is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of CMV disease. An indicator of active CMV infection is needed to facilitate the diagnosis of CMV disease in patients with AIDS or HIV infection. CMV p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.

Catalog Number: (BOSSBS-2438R-FITC)

Supplier: Bioss

Description: Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells. Disruption of this process has been implicated in a variety of diseases such as cancer. AVEN is a recently discovered protein that blocks apoptosis induced by Apaf-1 and caspase-9. It is thought that AVEN functions by binding to Bcl-xL, an antiapoptotic member of the Bcl-2 family, and to Apaf-1, possibly interfering with the ability of Apaf-1 to self-associate, suggesting that AVEN impedes Apaf-1-mediated caspase activation. Higher levels of AVEN mRNA are seen in patients with acute leukemia than in control patients, suggesting that AVEN may be useful as a prognostic indicator in leukemia patients.

UOM: 1 * 100 µl

Sale